Longitudinal changes in optoretinography provide an early and sensitive biomarker of outer retinal disease

Teng Liu, MS[1,2],

Benjamin Wendel, BS[1],

Jennifer Huey, MS, LCGC[1],

Vimal Prabhu Pandiyan, PhD[1],

Debarshi Mustafi, MD, PhD[1,3],

Jennifer R. Chao, MD, PhD[1],

Ramkumar Sabesan, PhD[1,2*]

[1]Department of Ophthalmology, University of Washington, Seattle, WA, 98109.

[2]Department of Bioengineering, University of Washington, Seattle, WA, 98195.

[3]Seattle Children's Hospital, Seattle, WA, 98105.

*Corresponding author email: rsabesan@uw.edu

Abstract

Objective:

To examine whether optoretinography (ORG) can provide greater sensitivity for

assessing the time-course of disease progression in Retinitis Pigmentosa compared to

standard clinical imaging in a longitudinal study,

Design:

Cohort, longitudinal study.

Participants:

Five non-syndromic RP patients and eight control subjects participated in the study.

Methods:

Clinical examination, imaging sessions and data analysis were all conducted at the

University of Washington. Five eyes of 5 patients diagnosed with RP, comparing

standard clinical imaging to ORG, were collected over a 21-month span between August

2022 and May 2024.

Main outcome and measures

ORG response to visual stimuli, ellipsoid zone (EZ) width and outer segment length (OS

length) were evaluated for longitudinal changes as markers of disease progression.

Results

The reduction in cone function with ORG over time exceeds that observed in standard

clinical markers of photoreceptor structure - EZ width and OS length. EZ width and OSL

decreased by 4.5% ± 5.9% and 6.5% ± 1.4%, respectively, approximately 9.9 and 6.9

times less than the reduction noted in ORG, respectively. The most notable degradation

was noted at the borders of the transition zone, where ORG showed progressive and

sub-clinical losses in photoreceptor function whereas standard OCT showed healthy,

unaffected outer retinal structure.

<u>Conclusions</u>

Optoretinography detects sub-clinical disease and reliably identifies longitudinal

markers of progression with greater sensitivity compared to standard clinical imaging.

The ability to detect functional changes in the outer retina prior to standard clinical

measures underscores its potential as a sensitive, accelerated and clinically-relevant

outcome measure to guide patient selection and their therapeutic response in future

clinical trials.

Introduction

Sensitive biomarkers of retinal health are critical for monitoring disease progression and evaluating therapeutic response [1,2]. Current clinical imaging tools are limited in their sensitivity and resolution to detect subtle degradation in retinal structure and function. This precludes early diagnosis and treatment, limiting visual recovery as there is a critical window for therapeutic intervention [3]. Optical coherence tomography (OCT) and fundus autofluorescence (FAF) are hallmark structural measures of the outer retinal complex. Primary biomarkers include the ellipsoid band width on OCT [4-8] and hyper-autofluorescent (hyper-AF) rings on FAF [9-12]. It remains unclear to what extent the remnant structure of photoreceptors still supports normal function. Furthermore, studies have shown that in advanced stages of disease, OCT and FAF reveal only minor changes over time, making it difficult to detect incremental progression or an accurate response to treatment [13,14]. Clinical functional assessments, including BCVA [15,16], perimetry [17] and electroretinogram (ERG) [18,19], offer complementary information about retinal integrity. BCVA and perimetry represent the cumulative output of the entire visual system and are thus limited in their cellular specificity. Moreover, mechanisms in the retina and cortex that compensate for photoreceptor loss can allow patients to largely ignore visual symptoms until late in the disease process [15,20,21]. The gold standard objective measure of retinal functional activity is ERG, but it lacks the spatial resolution to detect localized changes, particularly in advanced stages of disease [22]. The urgent need for a non-invasive and sensitive biomarker of retinal disease progression has taken on renewed importance in the light of recent gene therapy clinical trials that have shown promise to restore outer retinal function [23-28].

Optoretinography (ORG) marks a significant advance in the non-invasive and sensitive

monitoring of retinal structure and function *in vivo*. When implemented in an OCT, it

provides a direct optical measure of light-evoked photoreceptor activity [29-37] in

conjunction with the underlying three-dimensional structure responsible for the

functional assay. The activity is linked to the initial steps in vision that originate in the

outer retina - light absorption, photoisomerization, phototransduction and the visual

cycle [34,38]. A few recent studies have demonstrated the ability of ORG to detect sub-

clinical changes in RP [21,39,40], particularly in the transition zone at the border of healthy

and diseased areas, highlighting its potential for accurate disease assessment.

RP is the most common inherited retinal degeneration (IRD) and is the target of various

therapeutic approaches [23,41,42]. Whereas no approved treatments are available to halt

or reverse the progression of RP, several clinical trials are underway [43-45]. Clinical and

high-resolution adaptive optics (AO) imaging have revealed the common outer retinal

phenotypes in RP - reduction in EZ width [6-8,11,46,47], OS length [48-50] and cone density [6,8].

Visual acuity [51] and perimetry [17] reveal progressive visual field constriction that

eventually affects the central fovea. ERG [19,52-54] typically shows reduced or absent a-

and b-waves, reflecting photoreceptor degeneration and inner retinal remodeling.

Overall, these metrics show between 4-13 % annual rates of RP progression [6,19,55].

Here, in the first application of ORG to a longitudinal study, we test the hypothesis that

cone dysfunction measured with ORG precedes the deterioration exhibited by standard

clinical biomarkers in RP patients. We hypothesize that the ORG can detect

photoreceptors in their earliest stages of outer segment compromise, at the border

between the healthy-appearing central island and transition zone, where structural

imaging suggests normal status. This retrospective longitudinal study spanned 12 to 21

months in 5 RP patients and compared ORG findings with EZ width and OS length in

quantifying progression.

Method

<u>Study participants</u>

Five patients (ages 23–60 years-old (yo), mean: 33.4 yo) diagnosed with RP based on

clinical presentation and relevant family history at the Karalis Johnson Retina Center,

Department of Ophthalmology at University of Washington were enrolled in the study. All

participants underwent genetic testing through CLIA-approved labs and four (RP02 –

RP05) had a confirmed molecular genetic diagnosis (Table 1). Although genetic testing

for RP01 was inconclusive, their clinical exam, imaging, Goldmann Visual Fields, and

electrophysiology testing were consistent with RP. Research procedures followed the

tenets of the Declaration of Helsinki. Eight age-matched normal controls were also

enrolled in the study. Informed consent was obtained from all patients, and research

protocols were approved by the institutional review board of the University of

Washington (IRB#STUDY00002923). Patient characteristics are listed in Table 1.

Research imaging procedures were performed over three visits: baseline, first follow-up

(f/u #1), and second follow-up (f/u #2), with a minimum of six months between each

follow-up visit. The maximum length of follow-up ranged from 12 to 21 months.

Cycloplegia was induced by 1% tropicamide ophthalmic solution for imaging.

The study involved standard clinical testing including OCT (Spectralis HRA+OCT

system; Heidelberg Engineering, Vista, CA, USA), color fundus photography and fundus

autofluorescence (FAF) (Optos, Marlborough, MA, USA). These conventional measures

were compared to ORG (Figure 1).

ORG: imaging system, protocol and analysis

ORG was acquired using a custom-built, line-scan spectral domain OCT system with 3°

× 5.5° field-of-view, whose details are described previously [56]. First, after a 1-minute

dark adaptation, fifty OCT volumes were recorded at 32 Hz. Single OCT volumes were

reconstructed and registered with each other to compensate for small eye movements,

rendering an averaged, high signal-to-noise ratio OCT volume (Fig 1A) for further

analysis. Next, segmentation of the outer retinal layers – the inner-outer segment

(ISOS)-ellipsoid band and the outer segment tips, yielded en face 2D images of these

layers (Fig 1A) as well as the length of the cone outer segment (Fig 1B). Although EZ

width is a well-recognized clinical biomarker of RP, it reflects the preserved portion of

the photoreceptor inner segment and therefore does not provide information on outer

segment integrity. Sub-clinical changes, such as shortening of the outer segment, can

still occur within the EZ area in RP. Therefore, in addition to EZ width (Table 1) derived

from clinical OCT based on the presence of the ISOS-ellipsoid band (as determined by

three independent graders), this study also used the OS length as a structural measure

of disease status. Fig 1B shows the characteristic decline in OS length radiating

outward from the foveal center. Note that the measures of cone structure and function,

OS length, EZ width and ORG, were all obtained from the same retinal location for each

follow-up visit, facilitating spatially localized comparison between them.

The cone ORG, i.e. light-evoked activity in cone OS, was measured following a green

stimulus (532 ± 5 nm) of photon density 14.1×10^6 photons/μm^2, chosen to provide a

similar *and* high activation of L and M-cones. The cone ORG response is defined as the

change in the cone OS length evoked by a light stimulus as a function of time, as

illustrated in Fig. 1C. It is computed as the change in optical phase (converted to optical

path length (ΔOPL)) between the ISOS-EZ and cone outer segment tips (COST). In the

typical single-flash stimulus paradigm shown here, the ΔOPL exhibits a rapid, low

amplitude reduction immediately after stimulus onset, followed by a sharp increase and

a saturated plateau (Fig. 1C). Saturated ORG response is calculated as the average

ΔOPL over ~300 ms during the plateau, as shown in Fig. 1D. In a typical healthy

control, the saturated ORG scales linearly with OS length (and eccentricity), whereby

longer foveal OS exhibits larger ORG responses and shorter peripheral cones have

proportionally reduced ORG[56], as shown in Fig. 1B&D. The entire ORG procedure was

completed in 25 ± 10 mins.

<u>Test-retest variability and statistical analysis</u>

Figures 1C&F illustrate scatter plots of test-retest variability (left) for OS length and

ORG in normal controls, showing minimal changes over two visits, spaced 6-months

apart. Each scatter plot includes a linear fit line, which closely approximates the identity

line ($y = x$), indicating strong agreement between measurements from the two visits.

Figures 1C&F display Bland-Altman plots (right) for OS length and ORG. In these plots,

the mean difference (bias) between visits is close to zero for both parameters, indicating

no significant systematic bias. Most data points fall within the limits of agreement (±1.96

SD), suggesting minor measurement variability for both OS length and ORG.

To further assess the reliability and repeatability, test-retest variability was analyzed by

calculating the coefficient of variation (CV) (CV = (SD/Mean) ×100%) for EZ width, OS

length, and ORG across repeat measurements. Additionally, Wilcoxon signed-rank tests

were used to examine intra-subject variability in reductions of these metrics, providing a

means to analyze paired differences for non-normally distributed data. The CVs of 1.5%

for EZ width, 3.0% for OS length, and 4.0% for ORG, confirm comparable measurement

reliability across these metrics.

Figure 1. Overview of study design, illustrating the advanced structure-function assessment. OCT volumes

along with the segmented *en face* image at the inner/outer segment-ellipsoid zone (ISOS-EZ) and outer

segment tips (COST) help visualize the retinal structure (A). A zoomed-in view of OCT B-scans provides

the outer retinal profile (red line) from which the OS length is obtained and plotted as a function of

eccentricity in a color map (B). Warmer and cooler colors represent longer and shorter OS lengths

respectively. Retinal function is assessed by measuring the change in outer segment optical path length

(ΔOPL) evoked by a light stimulus (shaded green) – denoted as the ORG amplitude (D). The saturated

ORG amplitude is obtained from the time evolution of the functional response, shown in (D) for a near-

foveal (gray) and parafoveal (black) retinal location. The shaded areas around the solid lines indicate the

standard-deviation of repeat measurements. The variation of the saturated ORG is plotted as a function of

eccentricity in a color map (E). Test-retest (left) and Bland-Altman analysis (right) shows high repeatability

for both OS length (C) and ORG (F).

Results

Table 1 lists age, sex, genetic diagnosis, clinical presentations, follow-up duration, and

changes in BCVA and EZ width of the RP participants included in the study. Over the

course of follow up, there was minimal change in BCVA (Table 1). The EZ width

captured on a commercial OCT macular B-scan revealed variable progression across

the cohort. Study participants experienced a reduction in EZ width ranging from 0.9% to

15% (mean: 4.5% ± 5.9%) over varying follow-up periods of 12 to 21 months.

188   Table 1. Characteristics of study participants

Patient ID	Age range	Sex	Genotype	Clinical presentation description	Follow-up duration (months)	Change of BCVA study eye (logMAR)	Reduction of EZ width (µm, %)
RP01	26-30	F	Indeterminate	nyctalopia, myopia, "macular cysts"	16, 20	0	310 (15%)
RP02	26-30	M	*IMPDH1* c.942_944del, p.(Lys314del)	reduced peripheral vision, impaired dark adaptation	14, 21	0.08	72 (5.3%)
RP03	56-60	F	*RHO* c.165C>A, p.(Asn55Lys)	nyctalopia, increased glare while driving	9, 15	0.10	130 (13.5%)
RP04	21-25	F	*PRPF31* c.323-1G>T	nyctalopia, high myopia, blurring of central vision with flashes	6, 12	-0.10	23 (0.9%)
RP05	26-30	F	*RHO* c.68C>A, p.(Pro23His)	nyctalopia, reduced peripheral vision	8, 16	0	34 (1.5%)

The most significant EZ width progression of 15% over 20 months of follow-up was

seen in Subject RP01. We detail the complete procedure, including both the clinical and

advanced imaging with this subject as an example (Fig. 2). Clinical OCT B-scans and

FAF images in Fig. 2 (A-B) illustrate visible changes between baseline and follow-up

visits. Within the EZ area, where subtle and early changes might not be distinguishable

using clinical biomarkers alone, ORG imaging was applied to an area aligned with the

FAF (blue rectangle, white ellipse, Fig 2B & 2C). At baseline, near the border of the

healthy island and transition zone (yellow ellipse), a complete loss of OS tip reflection

precludes reliable OS length and ORG measurements. The OS length map shows a

radial decrease from the fovea to the periphery both at baseline and follow-up.

However, at follow-up, a reduction in OS length is noted at locations close to the edge of

the healthy zone, that is greater in magnitude for the temporal retina. The ORG map

follow-up reflects the patient's general trend of overall reduction in OS length, with the

temporal meridian showing the greater progression. In both OS length and ORG, the

progression is expectedly most evident at the frontier of degeneration at the border of

the healthy island and transition zone. Together, figures 2D-E demonstrate that, even in

healthy regions appearing intact on FAF and OCT, advanced ORG imaging not only

reveals progressive changes in retinal structure, but also reduced function over time.

Figure 2. Example longitudinal study analysis pipeline for RP01. (A) Clinical OCT B-scans from baseline

(top) and follow-up (bottom) visit. Red arrows indicate the fovea. Red & yellow dashed lines mark the EZ

width boundaries at baseline and follow-up respectively. (B) Fundus autofluorescence (FAF) from

baseline (top) and follow-up (bottom) visit. The white dashed ellipse outlines the EZ area, while the blue

rectangle marks the region selected for further OCT-ORG analysis. (C) E*n face* images for baseline (top)

and follow-up (bottom), with the corresponding EZ area from (B) marked as a white dashed ellipse. The

yellow ellipse highlights the area chosen for OSL and ORG analysis, based on the preservation of all

outer retinal layers. Maps of (D) OS length and (E) ORG amplitude are shown for baseline (top) and

follow-up (bottom). An outline is drawn in the OS length and ORG maps, as reference for comparison

between baseline and follow-up visits.

Figures 3A-3C display *en face* OCT images segmented at the ISOS-EZ, OS length

maps, and ORG amplitude maps for RP03, RP04 and RP05. The red boxes indicate

ROIs selected for ORG. The gradual reduction in OS length and ORG versus

eccentricity is evident both at baseline and follow-up for all cases, similar to normal

controls (Fig 1). In RP03, both OS length and ORG show a significant reduction along

the border of the healthy island and transition zone (Fig. 3B, yellow dashed line). The

difference in structural and functional readouts are apparent, where the OS length

shows a gradual reduction at the edge of the healthy zone, while the ORG shows more

drastic decline.

In RP04, OS length changes are minor and nearly indistinguishable upon visual

inspection of the color maps. Yet ORG reductions are observed, where only minor

changes are observed in cone structure as assessed by OS length (yellow arrows, Fig.

3). In the early-stage patient RP05, as defined by minimal symptoms and greater

preservation of clinical metrics, both OS length and ORG remained stable over time and

no changes were apparent upon visual inspection. Of note, RP03 (age range: 56 - 60

yo) and RP05 (age range: 26 - 30 yo) are both affected by variants in the *RHO* gene

(RP03: c.165C>A, p.Asn55Lys; RP05: c.68C>A, p.Pro23His in RP05), but exhibit

distinct progression patterns presumably due to their distinct genotypes and disease

stage.

Table 2. Comparison of ORG and OS length between RP patients and normal controls
in the healthy central island

Patient ID	ORG in healthy zone (nm)	OSL in healthy zone (µm)	Reduction of ORG (%)	Reduction of OSL (%)
RP01	545.8 ± 7.0	29.3 ± 0.6	32.1	5.2
RP02	690.9 ± 14.6	24.6 ± 0.2	14.1	20.4
RP03	577.4 ± 7.6	27.4 ± 0.3	28.2	11.3
RP04	645.1 ± 7.5	31.6 ± 0.3	19.8	-2.2
RP05	797.4 ± 13.5	28.1 ± 0.3	0.8	9.1
Control (n=8)	803.9 ± 9.6	30.9 ± 0.3	-	-

The ORG maps reveal a drop in amplitude at the borders of the healthy zone over time,

whereas OS length shows comparably lower reductions in the same areas. On the other

hand, OS length and ORG remain more stable near the fovea, indicating structural and

functional preservation in locations away from the active area of degeneration, i.e. the

transition zone. Although the disease progression is minimal near the fovea, the

absolute ORG magnitude is indeed decreased in RP compared to normal controls (see

Table 2). Previously, the reduction of ORG in the parafovea was shown to correspond

with normal microperimetry in RP [21]. These qualitative observations highlight nuanced

structural and functional changes detectable by ORG, even in regions previously

considered stable via standard clinical assessment. Next, we performed a quantitative

comparison between ORG, OS length and EZ-width as an objective basis for evaluating

progression in RP.

Figure 3. Longitudinal follow-up in RP03, RP04, and RP05, displaying the progression from the initial

baseline visit to the most recent follow-up. (A) Baseline and follow-up *en face* images at the ISOS-EZ band

and the corresponding ROIs (red) selected for OS length and ORG analysis. Maps of OS length and ORG

are shown in (B) and (C) respectively. Their corresponding color bars denote the variation in OS length and

ORG response amplitude. Yellow dashed lines and arrows indicate the same location for reference across

follow-ups.

To derive relevant metrics for disease and potential clinical trials, we divided the ORG

into three spatial sections for further assessment: ORGtot denoting the overall ORG

amplitude across the measurable region, where the measurable region is defined by the

presence of both the ISOS-ellipsoid and COST bands; ORG$edge$ denoting the ORG

response in the border region surrounding the healthy island; and ORG$cent$ denoting

the ORG response in the central healthy region. This is analogous to the *"hill of vision"*

metric [57,58] for documenting the rate of progression in established natural history studies

such as the *USH2A*-related retinal degeneration or RUSH2A study. ORG$edge$ and

ORG$cent$ were calculated based on the mean ORG of 10 regions of interest, each of

size 0.25° × 0.25°, near the border of the healthy island and in the central fovea

respectively (marked by white dots in Fig 4A). The ORGtot was calculated as the mean

ORG response for the whole measurable area (white dashed line in Fig. 4A). The

comparison between these spatially distinct metrics is shown in Fig. 4B. ORG$edge$ is

the most sensitive for assessing progression and demonstrates the largest reduction

over time, highlighting the active degradation at the boundary of the transition zone. The

corresponding changes in OS length for the same spatial sub-divisions - indicated as

OSLtot, OSL$edge$, and OSL$cent$ - are illustrated in Fig. 4C. The greater reduction in

OSL$edge$ compared to OSLtot and OSL$cent$ is evident in RP01, 03 and 04, while this

difference is not apparent for the other two cases.

With the knowledge that ORG*edge* was the most sensitive in detecting longitudinal

changes, we plotted the change of this metric for the two follow-ups (Figure 4D). It was

evident that by 9 months after their baseline visit, there was detectable disease

progression in RP03 and RP04, as indicated by the reduction in ORG*edge* at the first

follow-up – 65.1% and 13.5% respectively. For RP01 and RP02, the first follow up of 16

and 14 months respectively showed an ORG*edge* reduction of 34.9% and 40.7%

respectively. There was a notable decrease in ORG*edge* amplitude for all patients at

both follow-ups, apart from RP05: f/u #1: mean = 31.5% ± 6.7% (range: 3.6% - 65.1%)

and f/u #2: mean = 44.7% ± 5.3% (range: 4.3% - 76.7%). For RP01 – 03, the

progression was statistically significant for both follow-ups compared to baseline (p

<0.005). For RP04, the progression from baseline to 1st follow-up was not statistically

significant (p = 0.084), while the progression from baseline to the 2nd follow-up was

significant (p = 0.02). In these four cases, cone function deteriorated significantly in the

time-interval between the two follow-up visits, demonstrated by the larger ORG

reduction at the second follow-up. The most advanced stage patient within the cohort

(RP03) also demonstrated the largest reduction in ORG*edge* (65.1% and 76.7%

respectively at 9 and 15-month follow up).

Figure 4. Comparison of biomarkers for detecting RP disease progression. (A) The ORG maps are divided

into regions-of-interest (ROIs) (white circles) to allow regional comparison of photoreceptor dysfunction.

ORG*edge* and ORG*cent* are derived from ROIs at the border of the healthy island and in the central fovea,

respectively, while ORG*tot* is obtained from the entire ORG map. The fovea is indicated by a red star. (B)

Comparison of regional metrics derived from ORG, including ORG*tot*, ORG*edge*, and ORG*cent*. (C)

Corresponding metrics from OS length, including OSL*tot*, OSL*edge*, and OSL*cent* in (C). (D) Scatter and

bar plots showing the percentage reduction in ORG*edge* amplitude over time for the five RP patients, with

pink and purple shades representing the first and second follow-up visits, respectively. Connecting lines

illustrate ORG changes for the same imaged location across the different follow-ups. Statistical significance

values obtained from the Wilcoxon signed-rank test are noted for (D).

We then compared ORG*edge* to standard clinical metrics of outer retinal structure (Fig.

5). Comparison of the reduction in ORG*edge* against EZ width and OS length for the

most recent follow-up visits is shown. Note that OS length in Fig. 5 is obtained from the

same locations and regions-of-interest as the ORG*edge*, facilitating a direct comparison

between cone structure and function at the edge of the healthy island. Significantly

greater reduction in ORG*edge* amplitude was observed compared to OSL and EZ width

for RP01, 02, 03 and 04 ($p < 0.02$, Wilcoxon signed-rank test). For RP05, the small but

significant reduction in ORG*edge* was not accompanied by changes in EZ width.

Deterioration in cone structure, measured by a reduction in OSL and EZ, was less

pronounced; the change in OS length and EZ-width was 5.7% ± 1.2% and 4.5% ± 5.9%

respectively. The comparative reductions in EZ width versus OS length were not

statistically different except for in RP04. Overall, these findings demonstrate that ORG

detection of cone dysfunction precedes the loss of cone structure and provides an early

and otherwise sub-clinical biomarker of disease progression.

Figure 5. Comparison between ORG*edge*, OS length, and EZ-width for the five RP patients. Statistical

significance values obtained from the Wilcoxon signed-rank test are noted in the plot.

Discussion

This is the first study to assess longitudinal disease progression using ORG and

highlights its vast potential as a sensitive biomarker to precisely monitor progression of

outer retinal disease. While RP was chosen as an example of outer retinal degeneration

to assess the sensitivity of ORG to detect progression, the findings could be applicable

across a broad range of primary and secondary photoreceptor diseases, including

geographic atrophy in age-related macular degeneration (AMD) and other inherited

retinal diseases, where the structure and function of the outer retinal complex is

compromised [13,59,60]. The evolution of ORG used in this study, dubbed CoORG or

Coarse-scale ORG, does not require an adaptive optics module and sacrifices cellular

resolution for increased field-of-view and high-throughput, patient-friendly imaging [56].

Furthermore, patients with characteristics such as cataracts and excessive eye

movements that would preclude adaptive optics imaging are accessible within the

CoORG paradigm. Longitudinal study of the same patients and retinal locations over

time as demonstrated here offers inherent control over inter- and intra-subject

dependent factors that cause variability in the ORG, facilitating effective comparisons. In

the future, documenting the normative characteristics of the ORG versus eccentricity [56]

and age are important considerations for its wide-spread application.

Disease progression measured in ORG was compared to standard clinical assays. EZ

width in OCT is one of the key biomarkers that reflects the remnant inner-segment-EZ

structure of the photoreceptors. Here, we observed a 5% annual decline in EZ width in

our cohort, a finding that closely aligns with the 5-7% reduction rate reported in previous

studies [6,11]. While EZ width is a highly repeatable marker of advanced-stage outer

retinal degeneration [7,55], it does not convey functional information of the outer retina, nor

the viability of the photoreceptor outer segment. The constriction of hyper-AF rings

observed in FAF provides a biomarker for progression and is shown to have low test-

retest variability [55]. In RP, the annual horizontal and vertical rates of decline in hyper-AF

ring size were reported to be 4.1% and 4.0%, respectively [55]. In our study, we observed

similar rates of annual decline over a 5-year period for RP01, with horizontal and

vertical reductions of 4.1% and 3.4%, respectively.

As an add-on to OCT imaging, the ORG seamlessly integrates the assessment of

structure and function in the same platform with high sensitivity and spatial localization,

enabling the detection of functional changes that are anchored to clinically relevant

structural disease phenotypes such as EZ width and OS length. This is of critical

importance not only to compare against standard clinical measures of retinal structure

but also to obtain granular insight into the spatially heterogeneous pattern of disease

progression, such as in sectoral RP or geographic atrophy. As expected from the typical

pattern of progression in RP, from the periphery to the fovea, the highly variable border

region near the healthy island denoted by ORG*edge* showed the largest reduction over

time. In contrast, cone function in the central healthy area, denoted by ORG*cent*,

showed minimal change over time. (Figure 4B-C). However, cone function in the central

retina appeared to be compromised compared to controls even at the first time point, as

shown in Table 2, consistent with cross-sectional reports of ORG in RP [21,39]. The

ORG*tot* shows intermediate reduction in cone function compared to ORG*edge* and

ORG*cent* (Figure 4B). Overall, targeted regional analysis as introduced here for ORG,

based on previous suggestions for visual sensitivity [57,58] , enables capturing the spatially

localized and heterogenous pattern of disease progression as well as its comparison

against more global clinical metrics.

As shown in Fig 5, the reduction in cone function with ORG over time exceeds that

observed in EZ width and OS length. EZ width and OSL decreased by 4.5% ± 5.9% and

6.5% ± 1.4%, respectively (Fig. 5), approximately 9.9 and 6.9 times less than the

reduction noted in ORG*edge*. The ORG*edge* revealed an average reduction of 44.7% ±

5.3% including the very early-stage subject (RP05). If RP05 were excluded, the mean

ORG reduction in the remaining patients would increase to 54.8% ± 3.1%. The

comparison against ORG*tot* was more modest, where reduction in overall cone function

with ORG exceeds reductions in EZ width and OS length by 2.7x and 1.9x respectively

(12.3% for ORG vs. 4.5% for EZ width and 6.5% for OS length). Whereas the EZ width

can be treated as global metric of outer retinal health encompassing both the central

healthy island and the transition zone, the breakdown of OS length into *edge*, *center*

and *total* allows a more regional comparison between structure and function. Comparing

Figure 4B versus Figure 4C, it is evident that reduction in cone function over time

generally exceeds the reduction in OS length, whether assessed at the edge of the

healthy island, or as a whole.

The growing landscape of clinical trials, including the advancements in novel gene-

augmentation and gene-agnostic therapies for outer retinal diseases, underscores the

need for outcome measures that are safe, sensitive, and efficient. These measures are

particularly critical at early time points, when interventions may be most effective, or when

the therapeutic effects can be assessed earlier during a clinical trial. The approval of

voretigene neparvovec (Luxturna) for patients with *RPE65* mutations causing Leber

Congenital Amaurosis (LCA) represented a major advance in human vision restoration

using gene therapy. In addition, gene-editing for *CEP290*-associated retinal degeneration

has shown promising early results in clinical trials. In the context of geographic atrophy in

AMD, pegcetacoplan and avacincaptad pegol drugs have recently received FDA approval

for slowing disease progression by targeting the complement pathway [61-63]. EZ-width and

FAF are commonly used as clinical trial outcome measures. Efforts aimed at slowing or

reversing disease progression would benefit from a faster and more sensitive biomarker

that could ultimately lead to a shorter pathway for therapeutic testing and approval. This

study marks a significant step in this direction. The low test-retest variability (~4%)

coupled with the high sensitivity in detecting annual rates of reduction in cone function

highlights the potential of ORG to augment longitudinal studies of retinal disease and

response to therapeutic interventions. Accordingly, for a treatment to show measurable

effect with ORG, it would need to exhibit a minimum of 4% preservation or restoration of

cone function, while a treatment effect would be measurable in a significantly shorter

timespan compared to the current outcome measures.

<u>Limitations</u>

The study sample size is small, which may constrain statistical power and

generalizability, specifically with respect to drawing genotype-phenotype correlations. In

addition, the longitudinal study duration is limited to 21 months. Nevertheless, the ORG

measurements showed a high test-retest reliability over repeat measurements, and

significant disease progression was observed with ORG, even within the relatively short

timeframe and in those with limited progression with standard clinical imaging. Another

limitation of our study is the lack of longitudinal microperimetry in the same subjects.

The addition of this important biomarker would enable relating the change in visual field

to the degradation noted here in ORG and retinal structure. Previous work shows that

retinal areas with sub-normal cone function measured with ORG [21] may exhibit normal

visual sensitivity in RP, while IRD patients with loss of up to ~62% of cones still exhibit

normal visual acuity and sensitivity [15]. This suggests that subjective tests of visual

function may be less sensitive compared to objective tests of cone function such as

ORG in tracking progression.

Conclusions

Overall, this study highlights the ability of ORG to capture early changes in

photoreceptor function over time that are otherwise undetectable in standard clinical

imaging and often precede structural deterioration. By enabling the detection of

functional impairments before structural changes become apparent, ORG is poised to

play a pivotal role in clinical practice and therapeutic trials. As treatments continue to

evolve, the incorporation of ORG into clinical trials will accelerate the timeline and

improve sensitivity for monitoring treatment efficacy, ultimately shortening the

assessment period and enhancing patient outcomes.

Acknowledgements/Disclosure

The following sources of funding are acknowledged: NIH grant U01EY032055,

EY029710, Unrestricted grant from the Research to Prevent Blindness, Dawn's Light

Foundation, George and Martina Kren Professorship in Vision Research. Vimal

Pandiyan and Ramkumar Sabesan have filed a patent on the line-scan OCT technology

used here for optoretinography (PCT/US2020/029984).

References

1.   Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *The Lancet*. 2017;390(10097):849-860. doi:10.1016/S0140-6736(17)31868-8

2.   Schmetterer L, Scholl H, Garhöfer G, et al. Endpoints for clinical trials in ophthalmology. *Progress in Retinal and Eye Research*. 2023;97:101160. doi:https://doi.org/10.1016/j.preteyeres.2022.101160

3.   Scalabrino ML, Thapa M, Wang T, Sampath AP, Chen J, Field GD. Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa. *Nature Communications*. 2023;14(1):8256.

4.   Tao LW, Wu Z, Guymer RH, Luu CD. Ellipsoid zone on optical coherence tomography: a review. *Clinical & experimental ophthalmology*. 2016;44(5):422-430. doi: https://doi.org/10.1111/ceo.12685

5.   Scoles D, Flatter JA, Cooper RF, et al. Assessing photoreceptor structure associated with ellipsoid zone disruptions visualized with optical coherence tomography. *Retina*. 2016;36(1):91-103. doi:10.1097/IAE.0000000000000618

6.   Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa. *JAMA ophthalmology*. 2013;131(9):1143-1150. doi:10.1001/jamaophthalmol.2013.4160

7.   Hariri AH, Zhang HY, Ho A, et al. Quantification of ellipsoid zone changes in retinitis pigmentosa using en face spectral domain–optical coherence tomography. *JAMA ophthalmology*. 2016;134(6):628-635. doi:10.1001/jamaophthalmol.2016.0502

8.   Birch DG, Locke KG, Felius J, et al. Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa. *Ophthalmology*. 2015;122(4):833-839. doi:https://doi.org/10.1016/j.ophtha.2014.11.005

9.   Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. *Investigative ophthalmology & visual science*. 1995;36(3):718-729.

10.   Robson AG, Tufail A, Fitzke F, et al. Serial imaging and structure-function correlates of high-density rings of fundus autofluorescence in retinitis pigmentosa. *Retina*. 2011;31(8):1670-1679. doi:10.1097/IAE.0b013e318206d155

11.   Cabral T, Sengillo JD, Duong JK, et al. Retrospective analysis of structural disease progression in retinitis pigmentosa utilizing multimodal imaging. *Scientific Reports*. 2017;7(1):10347. doi:10.1038/s41598-017-10473-0

12.   Pole C, Ameri H. Fundus autofluorescence and clinical applications. *Journal of Ophthalmic & Vision Research*. 2021;16(3):432. doi:10.18502/jovr.v16i3.9439

13.   Cleland SC, Konda SM, Danis RP, et al. Quantification of geographic atrophy using spectral domain OCT in age-related macular degeneration. *Ophthalmology Retina*. 2021;5(1):41-48. doi:https://doi.org/10.1016/j.oret.2020.07.006

14.   Vámos R, Tátrai E, Németh J, Holder GE, DeBuc DC, Somfai GM. The structure and function of the macula in patients with advanced retinitis pigmentosa. *Investigative ophthalmology & visual science*. 2011;52(11):8425-8432. doi:https://doi.org/10.1167/iovs.11-7780

15.	Ratnam K, Carroll J, Porco TC, Duncan JL, Roorda A. Relationship between foveal
cone structure and clinical measures of visual function in patients with inherited retinal
degenerations. *Investigative ophthalmology & visual science*. 2013;54(8):5836-5847.
doi:https://doi.org/10.1167/iovs.13-12557
16.	Battaglia Parodi M, La Spina C, Triolo G, et al. Correlation of SD-OCT findings and
visual function in patients with retinitis pigmentosa. *Graefe's Archive for Clinical and*
Experimental Ophthalmology. 2016;254:1275-1279. doi:https://doi.org/10.1007/s00417-
015-3185-x
17.	Grover S, Fishman GA, Brown Jr J. Patterns of visual field progression in patients
with	retinitis	pigmentosa.	*Ophthalmology*.	1998;105(6):1069-1075.
doi:https://doi.org/10.1016/S0161-6420(98)96009-2
18.	Holder GE. Pattern electroretinography (PERG) and an integrated approach to
visual pathway diagnosis. *Progress in retinal and eye research*. 2001;20(4):531-561.
doi:https://doi.org/10.1016/S1350-9462(00)00030-6
19.	Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in
retinitis pigmentosa and cone-rod dystrophy. *Ophthalmology*. 1999;106(2):258-268.
doi:https://doi.org/10.1016/S0161-6420(99)90064-7
20.	Lee JY, Care RA, Kastner DB, Della Santina L, Dunn FA. Inhibition, but not
excitation, recovers from partial cone loss with greater spatiotemporal integration,
synapse	density,	and	frequency.	*Cell	reports*.
2022;38(5)doi:10.1016/j.celrep.2022.110317
21.	Wendel BJ, Pandiyan VP, Liu T, et al. Multimodal High-Resolution Imaging in
Retinitis Pigmentosa: A Comparison Between Optoretinography, Cone Density, and
Visual	Sensitivity.	*Invest	Ophthalmol	Vis	Sci*.	Aug	1	2024;65(10):45.
doi:10.1167/iovs.65.10.45
22.	Gerth C, Wright T, Héon E, Westall CA. Assessment of central retinal function in
patients with advanced retinitis pigmentosa. *Investigative ophthalmology & visual science*.
2007;48(3):1312-1318. doi:https://doi.org/10.1167/iovs.06-0630
23.	Pierce EA, Aleman TS, Jayasundera KT, et al. Gene editing for CEP290-
associated	retinal	degeneration.	*N	Engl	J	Med*.	2024;390:1972-1984.
doi:10.1056/NEJMoa2309915
24.	Lorenz B, Künzel SH, Preising MN, et al. Single Center Experience with Voretigene
Neparvovec Gene Augmentation Therapy in RPE65 Mutation–Associated Inherited
Retinal Degeneration in a Clinical Setting. *Ophthalmology*. 2024;131(2):161-178.
doi:https://doi.org/10.1016/j.ophtha.2023.09.006
25.	Van Gelder RN, Chiang MF, Dyer MA, et al. Regenerative and restorative medicine
for	eye	disease.	*Nature	medicine*.	2022;28(6):1149-1156.
doi:https://doi.org/10.1038/s41591-022-01862-8
26.	Roska B, Sahel J-A. Restoring vision. *Nature*. 2018;557(7705):359-367.
doi:https://doi.org/10.1038/s41586-018-0076-4
27.	Levin LA, Chiang MF, Dyer MA, et al. Translational roadmap for regenerative
therapies	of	eye	disease.	*Med*.	2023;4(9):583-590.
doi:https://doi.org/10.1016/j.medj.2023.06.005
28.	Rosin B, Banin E, Sahel J-A. Current status of clinical trials design and outcomes
in	retinal	gene	therapy.	*Cold	Spring	Harbor	Perspectives	in	Medicine*.
2024;14(7):a041301. doi:10.1101/cshperspect.a041301

29.   Hillmann D, Spahr H, Pfäffle C, Sudkamp H, Franke G, Hüttmann G. In vivo optical imaging of physiological responses to photostimulation in human photoreceptors. *Proceedings of the National Academy of Sciences*. 2016;113(46):13138-13143. doi:https://doi.org/10.1073/pnas.1606428113

30.   Cooper RF, Tuten WS, Dubra A, Brainard DH, Morgan JI. Non-invasive assessment of human cone photoreceptor function. *Biomedical optics express*. 2017;8(11):5098-5112. doi:https://doi.org/10.1364/BOE.8.005098

31.   Zhang P, Zawadzki RJ, Goswami M, et al. In vivo optophysiology reveals that G-protein activation triggers osmotic swelling and increased light scattering of rod photoreceptors. *Proceedings of the National Academy of Sciences*. 2017;114(14):E2937-E2946. doi:https://doi.org/10.1073/pnas.1620572114

32.   Zhang F, Kurokawa K, Lassoued A, Crowell JA, Miller DT. Cone photoreceptor classification in the living human eye from photostimulation-induced phase dynamics. *Proceedings of the National Academy of Sciences*. 2019;116(16):7951-7956. doi:https://doi.org/10.1073/pnas.1816360116

33.   Ma G, Son T, Kim T-H, Yao X. Functional optoretinography: concurrent OCT monitoring of intrinsic signal amplitude and phase dynamics in human photoreceptors. *Biomedical Optics Express*. 2021;12(5):2661-2669. doi:https://doi.org/10.1364/BOE.423733

34.   Pandiyan VP, Maloney-Bertelli A, Kuchenbecker JA, et al. The optoretinogram reveals the primary steps of phototransduction in the living human eye. *Science advances*. 2020;6(37):eabc1124. doi:10.1126/sciadv.abc1124

35.   Azimipour M, Valente D, Vienola KV, Werner JS, Zawadzki RJ, Jonnal RS. Optoretinogram: optical measurement of human cone and rod photoreceptor responses to light. *Optics letters*. 2020;45(17):4658-4661. doi:https://doi.org/10.1364/OL.398868

36.   Tomczewski S, Węgrzyn P, Borycki D, Auksorius E, Wojtkowski M, Curatolo A. Light-adapted flicker optoretinograms captured with a spatio-temporal optical coherence-tomography (STOC-T) system. *Biomedical Optics Express*. 2022;13(4):2186-2201. doi:https://doi.org/10.1364/BOE.444567

37.   Wongchaisuwat N, Amato A, Yang P, et al. Optical Coherence Tomography Split-Spectrum Amplitude-Decorrelation Optoretinography Detects Early Central Cone Photoreceptor Dysfunction in Retinal Dystrophies. *Translational Vision Science & Technology*. 2024;13(10):5-5. doi:https://doi.org/10.1167/tvst.13.10.5

38.   Pandiyan VP, Nguyen PT, Pugh Jr EN, Sabesan R. Human cone elongation responses can be explained by photoactivated cone opsin and membrane swelling and osmotic response to phosphate produced by RGS9-catalyzed GTPase. *Proceedings of the National Academy of Sciences*. 2022;119(39):e2202485119. doi:https://doi.org/10.1073/pnas.2202485119

39.   Lassoued A, Zhang F, Kurokawa K, et al. Cone photoreceptor dysfunction in retinitis pigmentosa revealed by optoretinography. *Proceedings of the National Academy of Sciences*. 2021;118(47):e2107444118. doi:https://doi.org/10.1073/pnas.2107444118

40.   Gaffney M, Connor TB, Cooper RF. Intensity-based optoretinography reveals sub-clinical deficits in cone function in retinitis pigmentosa. *Frontiers in Ophthalmology*. 2024;4doi:https://doi.org/10.3389/fopht.2024.1373549

41.   Busskamp V, Picaud S, Sahel J-A, Roska B. Optogenetic therapy for retinitis pigmentosa. *Gene therapy*. 2012;19(2):169-175. doi:https://doi.org/10.1038/gt.2011.155

42. Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. *Molecular Therapy*. 2021;29(2):442-463. doi:10.1016/j.ymthe.2020.11.029

43. Kwak JJ, Kim HR, Byeon SH. Short-term outcomes of the first in vivo gene therapy for RPE65-mediated retinitis pigmentosa. *Yonsei Medical Journal*. 2022;63(7):701. doi:https://doi.org/10.3349/ymj.2022.63.7.701

44. Florido A, Vingolo EM, Limoli PG, Cotento L. Mesenchymal stem cells for treatment of retinitis pigmentosa: short review. *HSOA JOURNAL OF STEM CELLS RESEARCH, DEVELOPMENT & THERAPY*. 2021;7(1)doi:10.24966/SRDT-2060/100066

45. Lam BL, Pennesi ME, Kay CN, et al. Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study. *Ophthalmology*. 2024;doi:https://doi.org/10.1016/j.ophtha.2024.02.023

46. Cai CX, Locke KG, Ramachandran R, Birch DG, Hood DC. A comparison of progressive loss of the ellipsoid zone (EZ) band in autosomal dominant and x-linked retinitis pigmentosa. *Investigative ophthalmology & visual science*. 2014;55(11):7417-7422. doi:https://doi.org/10.1167/iovs.14-15013

47. Tee JJ, Yang Y, Kalitzeos A, Webster A, Bainbridge J, Michaelides M. Natural history study of retinal structure, progression, and symmetry using ellipzoid zone metrics in RPGR-associated retinopathy. *American Journal of Ophthalmology*. 2019;198:111-123. doi:https://doi.org/10.1016/j.ajo.2018.10.003

48. Micevych PS, Wong J, Zhou H, et al. Cone structure and function in RPGR-and USH2A-associated retinal degeneration. *American journal of ophthalmology*. 2023;250:1-11. doi:https://doi.org/10.1016/j.ajo.2023.01.006

49. Hood DC, Lin CE, Lazow MA, Locke KG, Zhang X, Birch DG. Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography. *Investigative ophthalmology & visual science*. 2009;50(5):2328-2336. doi:https://doi.org/10.1167/iovs.08-2936

50. Sayo A, Ueno S, Kominami T, et al. Significant relationship of visual field sensitivity in central 10 to thickness of retinal layers in retinitis pigmentosa. *Investigative Ophthalmology & Visual Science*. 2018;59(8):3469-3475. doi:https://doi.org/10.1167/iovs.18-24635

51. Aizawa S, Mitamura Y, Baba T, Hagiwara A, Ogata K, Yamamoto S. Correlation between visual function and photoreceptor inner/outer segment junction in patients with retinitis pigmentosa. *Eye*. 2009;23(2):304-308. doi:https://doi.org/10.1038/sj.eye.6703076

52. Cideciyan AV, Jacobson SG. Negative electroretinograms in retinitis pigmentosa. *Investigative ophthalmology & visual science*. 1993;34(12):3253-3263.

53. Huang W-C, Liu P-K, Wang N-K. Electroretinogram (ERG) to evaluate the retina in cases of retinitis pigmentosa (RP). *Retinitis Pigmentosa*. Springer; 2022:111-122.

54. Chan H, Brown B. Investigation of retinitis pigmentosa using the multifocal electroretinogram. *Ophthalmic and Physiological Optics*. 1998;18(4):335-350. doi:https://doi.org/10.1046/j.1475-1313.1998.00374.x

55. Sujirakul T, Lin MK, Duong J, Wei Y, Lopez-Pintado S, Tsang SH. Multimodal imaging of central retinal disease progression in a 2-year mean follow-up of retinitis pigmentosa. *American journal of ophthalmology*. 2015;160(4):786-798. e4. doi:https://doi.org/10.1016/j.ajo.2015.06.032

56.   Jiang X, Liu T, Pandiyan VP, Slezak E, Sabesan R. Coarse-scale optoretinography
(CoORG) with extended field-of-view for normative characterization. *Biomedical Optics*
Express. 2022;13(11):5989-6002. doi:https://doi.org/10.1364/BOE.473475
57.   Smith TB, Parker M, Steinkamp PN, et al. Structure-function modeling of optical
coherence tomography and standard automated perimetry in the retina of patients with
autosomal   dominant   retinitis   pigmentosa.   *PLoS   One*.   2016;11(2):e0148022.
doi:https://doi.org/10.1371/journal.pone.0148022
58.   Duncan JL, Liang W, Maguire MG, et al. Baseline visual field findings in the
RUSH2A study: associated factors and correlation with other measures of disease
severity.   *American   journal   of   ophthalmology*.   2020;219:87-100.
doi:https://doi.org/10.1016/j.ajo.2020.05.024
59.   Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. *The*
Lancet. 2018;392(10153):1147-1159. doi:10.1016/S0140-6736(18)31550-2
60.   Aboshiha J, Dubis AM, Carroll J, Hardcastle AJ, Michaelides M. The cone
dysfunction syndromes. *British Journal of Ophthalmology*. 2016;100(1):115-121.
doi:https://doi.org/10.1136/bjophthalmol-2014-306505
61.   Chew EY. Complement inhibitors for the treatment of geographic atrophy. *The*
Lancet. 2023;402(10411):1396-1398. doi:10.1016/S0140-6736(23)01844-5
62.   Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad
pegol in patients with geographic atrophy (GATHER2): 12-month results from a
randomised, double-masked, phase 3 trial. *The Lancet*. 2023;402(10411):1449-1458.
doi:https://doi.org/10.1016/S0140-6736(23)01583-0
63.   Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for
geographic atrophy secondary to age-related macular degeneration: a randomized phase
2   trial.   *Ophthalmology*.   2020;127(2):186-195.
doi:https://doi.org/10.1016/j.ophtha.2019.07.011

648